Larotrectinib (tradename Vitrakvi) is a drug for the treatment of cancer.It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013. Reference standards of Larotrectinib API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
Larotrectinib
Catalogue No.:PA 12 1480000
CAS :
Molecular Formula : C21H22F2N6O2
Molecular Weight : 428.44
(S)-N-(5-Chloropyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
Catalogue No.:PA 12 1481000
Molecular Formula : C11H12ClN5O2
Molecular Weight : 281.7
(S)-1-benzyl-3-hydroxypyrrolidine-2,5-dione
Catalogue No.:PA 12 1481002
Molecular Formula : C11H11NO3
Molecular Weight : 205.21
(S)-1-benzylpyrrolidin-3-ol
Catalogue No.:PA 12 1481001
Molecular Formula : C11H15NO
Molecular Weight : 177.25
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
